Pharmaceuticals

Pfizer's GLP-1-RA Program: Obesity and Type 2 Diabetes Update

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus Pfizer Inc. has announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM). Moving …

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update Read More »

Novartis to acquire Chinook Therapeutics

Novartis to acquire Chinook Therapeutics

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)  Novartis has announced that it has entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic …

Novartis to acquire Chinook Therapeutics Read More »

Janssen's Cancer Care at ASCO and EHA

Janssen’s Transformational Cancer Care at ASCO and EHA

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting will feature …

Janssen’s Transformational Cancer Care at ASCO and EHA Read More »

Janssen Collaborates with CBMG to Develop CAR-T Therapies

Janssen Collaborates with CBMG to Develop CAR-T Therapies

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies  Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation …

Janssen Collaborates with CBMG to Develop CAR-T Therapies Read More »

Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

Sanofi has simplified its contractual agreements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.).  Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S. …

Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements Read More »